Neuberger Berman Group
DNA icon

Neuberger Berman Group’s Ginkgo Bioworks DNA Stock Holding History

Neuberger Berman Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,593
Closed -$34.7K – 1951
2024
Q2 		$34.7K Sell
2,593
-16,128
-86% -$481K ﹤0.01% 1854
2024
Q1 		$869K Sell
18,721
-69,851
-79% -$3.62M ﹤0.01% 1325
2023
Q4 		$5.99M Buy
88,572
+35,326
+66% +$2.16M ﹤0.01% 1028
2023
Q3 		$3.86M Buy
53,246
+212
+0.4% +$16.9K ﹤0.01% 940
2023
Q2 		$3.95M Sell
53,034
-3,892
-7% -$230K ﹤0.01% 941
2023
Q1 		$3.03M Sell
56,926
-1,110
-2% -$70.3K ﹤0.01% 984
2022
Q4 		$3.92M Buy
58,036
+14,100
+32% +$1.3M ﹤0.01% 914
2022
Q3 		$5.48M Buy
43,936
+1,191
+3% +$142K 0.01% 864
2022
Q2 		$4.07M Sell
42,745
-8,190
-16% -$999K ﹤0.01% 947
2022
Q1 		$8.21M Buy
50,935
+2,532
+5% +$493K 0.01% 845
2021
Q4 		$16.1M Sell
48,403
-17,043
-26% -$8.1M 0.01% 740
2021
Q3 		$30.3M Buy
+65,446
New +$31.9M 0.03% 581

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neuberger Berman Group's DNA Position: Q3 2024 in Review

Neuberger Berman Group sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 2,593 shares — an estimated $34.7K sold.

Neuberger Berman Group first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $30.3M in Q3 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Neuberger Berman Group reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 2,593 Ginkgo Bioworks shares in Q3 2024, an estimated $34.7K.
  • Neuberger Berman Group first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Neuberger Berman Group's Ginkgo Bioworks position peaked at $30.3M in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Neuberger Berman Group's 13F filing for Q3 2024, filed 14 Nov 2024.